CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

A Phase 3 multicentre, randomised, open-label extension study to evaluate the long-term safety and tolerability of oral ubrogepant in the acute treatment of migraine with or without aura

Ubrogepant (MK-1602) Study title/design: A Phase 3 multicenter, randomized, open-label extension study to evaluate the long-term safety and tolerability of oral ubrogepant in the acute treatment of migraine with or without aura Trial NCT02873221: https://clinicaltrials.gov/ct2/show/NCT02873221?term=ubrogepant&rank=3 Aim To evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 …

Read more »

A Phase 3, multicentre, randomised, double-blind, placebo controlled single attack study to evaluate the efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine (ACHIEVE I)

Ubrogepant (MK-1602) Study title/design: A Phase 3, multicentre, randomised, double-blind, placebo controlled single attack study to evaluate the efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine (ACHIEVE I) Trial NCT02828020: https://clinicaltrials.gov/ct2/show/NCT02828020?term=ubrogepant&rank=2 Aim To evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo …

Read more »

A Phase 2 dose-finding study of MK-1602 in the treatment of acute migraine (MK-1602-006)

Ubrogepant (MK-1602) Study title/design: A Phase 2 dose-finding study of MK-1602 in the treatment of acute migraine (MK-1602-006) Trial NCT01613248: https://clinicaltrials.gov/ct2/show/NCT01613248 Aim To assess the effectiveness, safety and tolerability of a range of doses of MK-1602 versus placebo in the treatment of acute migraine. Study design Ubrogepant 1, 10, 25, 50 and 100 mg single …

Read more »

A Phase 3, multicentre, randomised, double-blind, placebo controlled single attack study to evaluate the efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine (ACHIEVE II)

Ubrogepant (MK-1602) Study title/design: A Phase 3, multicentre, randomised, double-blind, placebo controlled single attack study to evaluate the efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine (ACHIEVE II) Trial NCT02867709:  https://clinicaltrials.gov/ct2/show/NCT02867709?term=ubrogepant&rank=1 Aim To evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo …

Read more »